Novo Nordisk reported a 65% increase in Q1 2026 operating profit, driven by a provision reversal related to the US 340B Drug Pricing Program and strong sales of its new Wegovy pill for obesity. Adjusted sales excluding the provision reversal fell 4% due to lower prices but were supported by GLP-1 volume growth. The Wegovy pill, launched in January 2026, quickly reached over 2 million prescriptions, marking the strongest GLP-1 launch in the US. Novo Nordisk raised its 2026 outlook, expecting adjusted sales and operating profit growth between -4% and -12% at constant exchange rates, reflecting confidence in GLP-1 product demand and ongoing pipeline progress.
Novo Nordisk has initiated a share repurchase programme worth up to DKK 15 billion, starting from February 4, 2026, and running for 12 months. As of May 22, 2026, the company has repurchased over 17 million B shares at an average price of DKK 262.22 ...
Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, mea...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
